Research Paper Volume 12, Issue 22 pp 22975—23003

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

Figure 2. KIF14 is upregulated in sorafenib-resistant HCC cells. (A and B) Sorafenib-resistant Huh7-SR and HepG2-SR cells and the corresponding parent cells were incubated with 0, 2.5, or 5 μM sorafenib for 48 h. KIF14 mRNA levels were measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (B) The relative KIF14 mRNA levels of cells treated with 0 μM sorafenib were normalized to 1. (C and D) Sorafenib-resistant Huh7-SR and HepG2-SR cells and the corresponding parent cells were incubated with 0 or 5 μM sorafenib for 48 h. The protein expression profiles were detected by western blotting (C). The density of each band was normalized to that of β-actin (D). (E) Huh7-SR and Huh7 cells were stained with anti-KIF14 Ab (red) and DAPI (cellular nuclei, blue) and viewed with an inverted fluorescence microscope. (F) The KIF14 expression was used for survival analysis based on the TCGA database. The data represent three independent experiments. Scale bar = 10 μm. “*” Indicates P<0.05, and “**” indicates P<0.001; “‡” indicates P<0.001 versus untreated parent cells.